| | JULY 20186CIOReviewToday, the winds of change are most prominent in the biotechnology industry that is adopting a host of technology solutions to improve operational efficiency and performance across multiple streams. In its pursuit of precision medicine, new drug discoveries, or gaining insights to improve crop productivity, the biotechnology space is reaping the varied benefits of artificial intelligence, the internet of things, and machine learning amongst others. Furthermore, a medley of technologies as diverse as cloud, blockchain, and 3D printing are profoundly impacting the arena. While cloud can provide the scale for analyzing the massive data sets, the paramount issue of security, validation, regulation, and compliance has to be taken into consideration at all levels. Due to its sensitive nature, healthcare data merits blockchain technology to protect the privacy clause. Though a new entrant, 3D printing is arming the scientific fraternity to print biomaterials in the shape of human organs to save lives from life-threatening medical and physical conditions.Biotechnology companies are weaving technology into their workflow to automate, innovate, and be ahead of customer expectations while complying with numerous standards and regulations. Continuous manufacturing coupled with agile methodologies in tandem with robotic process automation are drastically reducing the production timelines and cost. Likewise, advanced analytics that has AI in tow can aggregate and synthesize information from the innumerable data sources and holds the key to accelerate the long-drawn drug discovery process. AI's powerful insights can throw light on the causes of certain health conditions by reading the patient's whole genome sequence to initiate the right treatment plans. As breakthroughs in gene sequencing to editing and therapeutic science continue to tumble out, next-gen technologies have to essentially work alongside human intelligence to create a better world. As the amazing capabilities of technology push the envelope in genetic engineering and synthetic food among others, the biotechnology industry is at the threshold of reimagining science.Let us know your thoughts.Jeevan George Managing Editoreditor@cioreview.comEditorialReimagining ScienceCopyright © 2018 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.CIOReviewJULY - 10 - 2018Editorial StaffSalesAaron PierceAkanksha MinzKuheli BiswasCarolynn WaltersKyle SummersRussell ThomasKatherine Joneskatherine@cioreview.comVisualizersIssac GeorgeGokul KGManaging EditorJeevan GeorgeBIOTECH SPECIAL*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffContact Us:Phone:510.402.1463Fax:510-894-8405Email:sales@cioreview.comeditor@cioreview.commarketing@cioreview.comJULY - 10 - 2018, Vol 07 SE 51 Published by ValleyMedia, Inc.To subscribe to CIOReviewVisit www.cioreview.com CIOReview
< Page 5 | Page 7 >